Are Peptides Legal in Alabama? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Alabama as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Alabama attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Alabama statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Alabama has scheduled or banned on its own. The Alabama Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Alabama's licensing boards have also spoken to peptide prescribing by clinics and medspas, which is where state-level risk actually sits (details below). Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Alabama at a glance

State controlled-substances law: Ala. Code § 20-2-1 et seq. (Alabama Uniform Controlled Substances Act); schedules at §§ 20-2-23 to 20-2-31 (codes.findlaw.com)
Human growth hormone under state law: No state provision located; the federal statute applies
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: The Alabama Board of Pharmacy petitioned the Board of Medical Examiners for a declaratory ruling on physicians buying and compounding GLP-1s. The petition states that semaglutide salt forms and research-grade powder are not FDA approved and that only prescription-quality active ingredient may be used, and that suppliers shipping into Alabama need a Board of Pharmacy permit. The Board of Medical Examiners ruled (considered 18 July 2024) that physicians may not compound with non-prescription-quality ingredients, must buy only from Board-permitted entities, and must follow USP standards (2024-07-18) (albme.gov)
Medical board on peptide prescribing: The Board of Medical Examiners' Fraudulent Activity Alert warns physicians that most semaglutide and tirzepatide sold online is counterfeit, often Chinese-sourced vials, notes the FDA bar on semaglutide sodium and acetate salt forms in compounding, and asks physicians approached by such sellers to report to the Board's investigations department. No BPC-157 or peptide-clinic statement was found (albme.gov)
GLP-1 by telehealth: Yes. Under Ala. Code §§ 34-24-700 to 707 no initial in-person exam is needed; if a physician treats the same patient by telehealth more than four times in twelve months for the same unresolved condition, the patient must be seen in person within twelve months or referred. The in-person rule for controlled substances does not affect GLP-1s. Out-of-state physicians need an Alabama licence unless they treat fewer than ten patients or ten days a year. (albme.gov)
State-level enforcement, 2023 to 2026: 2 actions found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Alabama, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Alabama:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Alabama. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Alabama law adds

Alabama's controlled-substances law (Ala. Code § 20-2-1 et seq. (Alabama Uniform Controlled Substances Act); schedules at §§ 20-2-23 to 20-2-31) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Alabama's schedules or in a Alabama-specific ban as of September 2026. That is the position in most states.

Human growth hormone

The Bureau could not locate a Alabama provision on human growth hormone. Treat the federal statute, 21 U.S.C. section 333(e), as the rule that applies.

Compounded semaglutide and tirzepatide

2024-07-18. The Alabama Board of Pharmacy petitioned the Board of Medical Examiners for a declaratory ruling on physicians buying and compounding GLP-1s. The petition states that semaglutide salt forms and research-grade powder are not FDA approved and that only prescription-quality active ingredient may be used, and that suppliers shipping into Alabama need a Board of Pharmacy permit. The Board of Medical Examiners ruled (considered 18 July 2024) that physicians may not compound with non-prescription-quality ingredients, must buy only from Board-permitted entities, and must follow USP standards. (albme.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

The Board of Medical Examiners' Fraudulent Activity Alert warns physicians that most semaglutide and tirzepatide sold online is counterfeit, often Chinese-sourced vials, notes the FDA bar on semaglutide sodium and acetate salt forms in compounding, and asks physicians approached by such sellers to report to the Board's investigations department. No BPC-157 or peptide-clinic statement was found. (albme.gov)

Buying, possessing and using research peptides in Alabama

No Alabama provision specific to possessing unscheduled research peptides was found; the federal misbranding and unapproved-drug rules bind sellers. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into Alabama is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Under Ala. Code §§ 34-24-700 to 707 no initial in-person exam is needed; if a physician treats the same patient by telehealth more than four times in twelve months for the same unresolved condition, the patient must be seen in person within twelve months or referred. The in-person rule for controlled substances does not affect GLP-1s. Out-of-state physicians need an Alabama licence unless they treat fewer than ten patients or ten days a year. (albme.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Alabama law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Alabama

2025-11-10. Attorney General Steve Marshall sued Aurora IV and Wellness of Cullman under the Deceptive Trade Practices Act for injecting patients with research-use-only semaglutide and tirzepatide marketed as pharmaceutical grade, and obtained a restraining order, a closure order and an asset freeze. (alabamaag.gov)
2026-01-12. The Aurora IV and Wellness case settled: $17,267.50 in restitution, $7,000 in penalties, permanent closure, the owners barred from direct patient care and the nurse owner's licence surrendered. (alabamaag.gov)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. The full text of Ala. Code § 20-2-27 (Schedule III) could not be opened from an accessible source, so whether Alabama lists human growth hormone in its own schedules is unverified. Alabama is the clearest example of a state attorney general shutting a clinic for using research-grade GLP-1s on patients.

Frequently asked questions

Is BPC-157 legal in Alabama?

Alabama has not scheduled BPC-157, so possessing it is not a Alabama offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Alabama?

Yes. Under Ala. Code §§ 34-24-700 to 707 no initial in-person exam is needed; if a physician treats the same patient by telehealth more than four times in twelve months for the same unresolved condition, the patient must be seen in person within twelve months or referred. The in-person rule for controlled substances does not affect GLP-1s. Out-of-state physicians need an Alabama licence unless they treat fewer than ten patients or ten days a year. The Alabama Board of Pharmacy position on compounded versions: The Alabama Board of Pharmacy petitioned the Board of Medical Examiners for a declaratory ruling on physicians buying and compounding GLP-1s. The petition states that semaglutide salt forms and research-grade powder are not FDA approved and that only prescription-quality active ingredient may be used, and that suppliers shipping into Alabama need a Board of Pharmacy permit. The Board of Medical Examiners ruled (considered 18 July 2024) that physicians may not compound with non-prescription-quality ingredients, must buy only from Board-permitted entities, and must follow USP standards.

Is HGH legal in Alabama?

Only with a valid prescription for an approved use. The Bureau did not locate a Alabama provision; federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Alabama fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.